SCHEMBL1969404

SCHEMBL1969404

Clc1cccc(-c2[c]n[nH]c2)c1Cl

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
IDO1 P14902 1/20 0.41
NOTUM Q6P988 2/20 0.38
NUDT1 P36639 5/20 0.37
CYP2D6 P10635 1/20 0.36
MAOA P21397 1/20 0.36
MAPK1 P28482 1/20 0.36
ADRA1A P35348 1/20 0.36
SCN4A P35499 1/20 0.36
BLM P54132 1/20 0.36
PMP22 Q01453 1/20 0.36
PDE3A Q14432 1/20 0.36
SCN5A Q14524 1/20 0.36
SCN9A Q15858 1/20 0.36
SCN2A Q99250 1/20 0.36
SCN3A Q9NY46 1/20 0.36
SCN10A Q9Y5Y9 1/20 0.36
CNR2 P34972 4/20 0.34
CNR1 P21554 2/20 0.34
GRM5 P41594 1/20 0.34
P2RX7 Q99572 3/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL979802 0.85 IDO1 (0.39) IDO1NOTUMCYP2D6
SCHEMBL294602 0.71 PIK3CD (0.33) NUDT1CNR2P2RX7
SCHEMBL1967310 0.70 IDO1 (0.38) IDO1NOTUMMAPK1
SCHEMBL70877 0.70 IDO1 (0.40) IDO1MAPK1ALOX15
SCHEMBL292783 0.70 RAB9A (0.38) IDO1NOTUMCYP2D6MAPK1ALOX15
SCHEMBL440943 0.68 TSHR (0.52) IDO1NOTUMNUDT1CYP2D6MAOA
SCHEMBL978671 0.68 ALDH1A1 (0.44) MAPK1ALOX15
SCHEMBL8755319 0.67 IDO1 (0.47) IDO1NOTUMNUDT1CYP2D6MAOA
SCHEMBL7861029 0.66 NUDT1 (0.49) IDO1NOTUMNUDT1CYP2D6MAOA
SCHEMBL5791176 0.66 IDO1 (0.50) IDO1NOTUMNUDT1CYP2D6MAOA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2334683-B1 SATURATED BICYCLIC HETEROCYCLIC DERIVATIVES AS SMO ANTAGONISTS MSD ITALIA SRL (IT) 2017-03-22 EP disclosed
US-8470823-B2 Saturated bicyclic heterocyclic derivatives as SMO antagonists INSTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI S.R.L. (IT) 2013-06-25 US disclosed
US-20110183989-A1 SATURATED BICYCLIC HETEROCYCLIC DERIVATIVES AS SMO ANTAGONISTS Instituto di Ricerche di Biologia Molecolare P. Ang 2011-07-28 US disclosed
EP-2334683-A1 SATURATED BICYCLIC HETEROCYCLIC DERIVATIVES AS SMO ANTAGONISTS Istituto di ricerche di Biologia Molecolare P. Angeletti S.R.L. (IT) 2011-06-22 EP disclosed
WO-2010023480-A1 SATURATED BICYCLIC HETEROCYCLIC DERIVATIVES AS SMO ANTAGONISTS ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI S.P.A. (IT) 2010-03-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110183989-A1 SATURATED BICYCLIC HETEROCYCLIC DERIVATIVES AS SMO ANTAGONISTS SMO, SHH, GLI1 IDO1 2975/4885NOTUM 1573/4885NUDT1 2181/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.